Group 1 - The company Tianyu Bio-Technology Co., Ltd. plans to issue shares to a specific group, with the aim of raising funds to supplement working capital and repay debts [2][11][14] - The issuance will involve a maximum of 71,028,297 shares, which is capped at 30% of the company's total share capital prior to the issuance [13][15] - The share price is set at 6.55 RMB per share, which is not less than 80% of the average trading price over the 20 trading days prior to the pricing benchmark date [12][29] Group 2 - The issuance is characterized as a related party transaction, as the shares will be fully subscribed by Shanghai Daoyun Asset Management Co., Ltd., controlled by the company's actual controller, Luo Weiguo [10][15] - The company has a high debt ratio, with figures of 59.13%, 74.51%, 77.96%, and 75.91% at the end of the reporting periods, indicating significant financial pressure [10] - The funds raised will be used entirely for operational needs and debt repayment, which is expected to optimize the company's capital structure and enhance its sustainability [11][14] Group 3 - The company aims to enhance its control stability through this issuance, as the actual controller's stake will increase, reflecting confidence in the company's future [10][11] - The issuance is not expected to change the company's control structure, as the actual controller will maintain a significant voting power post-issuance [15] - The company has established a profit distribution policy to ensure transparency and stability in shareholder returns, aligning with regulatory guidelines [4][10]
天域生物: 2025年度向特定对象发行A股股票预案